Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.54 |
| ▸ | POLA1 | P09884 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769286 | 0.90 | POLA1 (0.59) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537440 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929178 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| SCHEMBL4576331 | 0.90 | POLG (0.58) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929175 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| SCHEMBL13468595 | 0.90 | POLG (0.58) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21006164 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21007902 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561539 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14853857 | 0.90 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2015023664-A2 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2012177856-A2 | COGNITION MODIFICATION | ADISPELL, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2008125116-A2 | UPAR INHIBITION | AARHUS UNIVERSITET (DK) | 2008-10-23 | — | — | WO | disclosed |
| EP-1793006-A2 | Nucleic acid ligands and improved methods for producing the same | GILEAD SCIENCES, INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6849610-B1 | Polynucleotide ligands as anti-viral agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2001038341-A1 | POLYNUCLEOTIDE LIGANDS AS ANTI-VIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | CHRNG, CHRM3, CHRNA5 | POLG 2986/4885P2RY2 1153/4885P2RY4 1481/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | POLG 967/4885P2RY2 1820/4885P2RY4 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.